Biomedical Engineering

Cleveland Clinic’s Department of Biomedical Engineering is committed to investigation, innovation and translation of scientific discoveries to enhance patient care. Medical innovation is at the heart of our mission – indeed, our "calling" – and we have a proven track record of patenting and product commercialization.

Cleveland Clinic Innovations, the commercialization arm of Cleveland Clinic, has helped Biomedical Engineering patent therapies in cardiology, urology and neurology. Medical Device Solutions designs and manufactures innovative medical devices and products, and has assisted Biomedical Engineering in the creation of such therapies as the oxygen tension telemetry system and the continuous flow artificial heart.

Success Story

Cleveland Clinic, working with Volcano (now Philips), helped create the industry-leading intravascular ultrasound (IVUS) product line for coronary plaque characterization. This technology uses advanced, proprietary spectral analysis techniques to classify plaque into four tissue types, with 93-97% accuracy.

Success Story

The Regenerative Medicine Laboratory, led by George Muschler, MD, is using advanced imaging and robotic tools to create a novel platform for optimizing tissue-derived, colony-founding connective tissue progenitors. The work will advance the field of cell manufacturing, specifically the expansion of human mesenchymal stromal cells (MSCs), and will greatly improve the quality and reproducibility of MSC manufacturing and use in clinical therapies, drug development and research. Dr. Muschler was awarded $3.3 million from the National Institutes of Health to fund this innovative research.

Department News


BME Researcher Receives Award from the Clinical Research Forum for Pioneering Bionic Arm Study

Dr. Marasco was honored for engineering a prosthetic that allows the wearer to “think” and function like an able-bodied person.

Read More


Cleveland Clinic Model Predicts the Risk of Hospital Readmissions

Dr. Misra-Hebert and colleagues assessed a Cleveland Clinic model’s ability to predict the likelihood that a patient would need to be readmitted to the hospital within 30 days of discharge.

Read More


Three-Dimensional Organoid Models May Help Improve Drug Therapy for Brain Tumors

In their study, Drs. Hubert, Sundar and Shakya, and colleagues suggest that organoids can model patient-like drug resistance similar to that seen in human brain tumors.

Read More


Photo   Gallery